About 96% of previously untreated hepatitis C patients who took AbbVie's experimental interferon-free regimen had no detectable levels of the virus after 12 weeks of therapy, a late-stage trial found. The trial, the first of six Phase III studies evaluating the three-drug regimen, involved patients with genotype 1 virus with no indications of liver cirrhosis. The firm plans to submit the drug for approval next year.

Full Story:

Related Summaries